Targeting human CD2 by the monoclonal antibody CB.219 reduces intestinal inflammation in a humanized transfer colitis model

Clin Immunol. 2015 Mar;157(1):16-25. doi: 10.1016/j.clim.2015.01.004. Epub 2015 Jan 14.


The cell adhesion molecule CD2 facilitates antigen-independent T-cell activation and CD2 deficiency or blockade reduces intestinal inflammation in murine models. We here aimed to evaluate the therapeutic potential of monoclonal antibodies (mAb) specific for human CD2 in colitis treatment. Transfer colitis induced by naïve CD4(+) T cells expressing human CD2 was treated with anti-human CD2 mAb. The mAb CB.219 protected from severe colitis in a preventive treatment regimen, while therapeutic treatment ameliorated intestinal inflammation. Diminished intestinal tissue damage was paralleled by a profound suppression of lamina propria lymphocytes to produce pro-inflammatory cytokines and tumor necrosis factor α as well as the neutrophil chemoattractant CXC motif ligand 1 and the CC chemokine ligand 3. Furthermore, infiltration with macrophages and T cells was low. Thus, reduced intestinal inflammation in our humanized colitis model by targeting CD2 on T cells with the mAb CB.219 suggests a novel approach for colitis treatment.

Keywords: Human CD2; IBD mouse model; Monoclonal antibody CB.219; Reduced intestinal inflammation; Transfer colitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • CD2 Antigens / metabolism*
  • Cytokines / metabolism
  • Disease Models, Animal
  • Drug Delivery Systems
  • Humans
  • Inflammation / drug therapy
  • Inflammatory Bowel Diseases / physiopathology
  • Inflammatory Bowel Diseases / therapy*
  • Intestines / drug effects
  • Intestines / physiopathology*
  • Mice


  • Antibodies, Monoclonal
  • CD2 Antigens
  • Cytokines